logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Clozapine for refractory schizophrenia : The Illinois experience.

    Article, Communication - En anglais

    National Consensus Conference on the Pharmacoeconomics of Treatment-Resistant Schizophrenia. Dallas, TX, USA, 1997/10/04.

    Based upon the Illinois Department of Mental Health and Developmental Disabilities'computerized clinical information system, with its integration of client-specific clinical data, a 5-year retrospective study was designed to determine the clinical effectiveness and economic impact of the use of clozapine for treatment-resistant schizophrenia.

    The study sample consisted of 518 hospitalized, treatment-resistant patients.

    At the end of 5 years, 78% were well maintained on clozapine.

    Two hundred forty-three patients had been discharged to the community, and 62 had been transferred for treatment of medical or surgical problems.

    Clozapine treatment was discontinued in 115 patients (22%). The drug was well tolerated, with a very low incidence of agranulocytosis.

    Cost savings resulting from the discharge of the 243 clozapine-treated patients amounts to approximately $20 million per year.

    A disease management algorithm has been developed allowing physicians to begin clozapine treatment for patients not successfully treated with 2 prior antipsychotic agents.

    Adherence to this protocol throughout the state's mental health system would result in even greater savings.

    Mots-clés Pascal : Schizophrénie, Résistance traitement, Chimiothérapie, Clozapine, Neuroleptique, Atypique, Psychotrope, Efficacité traitement, Analyse coût, Economie santé, Illinois, Etats Unis, Amérique du Nord, Amérique, Homme, Psychose, Dibenzodiazépine

    Mots-clés Pascal anglais : Schizophrenia, Negative therapeutic reaction, Chemotherapy, Clozapine, Neuroleptic, Atypical, Psychotropic, Treatment efficiency, Cost analysis, Health economy, Illinois, United States, North America, America, Human, Psychosis

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0185980

    Code Inist : 002B02B03. Création : 16/11/1999.